Lymphokine Patents (Class 424/85.1)
  • Patent number: 11436732
    Abstract: Lesions associated with acute ischemic stroke are automatically segmented in images acquired with computed tomography (“CT”) using a trained machine learning algorithm (e.g., a neural network). The machine learning algorithm is trained on labeled data and associated CT data (e.g., non-contrast CT data and CT angiography source image (“CTA-SI”) data). The labeled data can include segmented data indicating lesions, which are generated by segmenting diffusion-weighted magnetic resonance images acquired within a specified time window from when the associated CT data were acquired. CT data (e.g., non-contrast CT data and CTA-SI data) acquired from a subject are then acquired and input to the trained machine learning algorithm to generate output as segmented CT data, which indicate lesions in the subject.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: September 6, 2022
    Assignee: The General Hospital Corporation
    Inventors: Ona Wu, Ramon Gilberto Gonzalez
  • Patent number: 11426449
    Abstract: Methods and compositions for treating and alleviating symptoms of irradiation injuries, therapeutic radiation intervention and/or anti-cancer therapies in a subject via pulmonary airway administration of granulocyte macrophage colony stimulating factor (GM-CSF) or a compound with similar affinity to the specific alveolar GM-CSF receptor to enhance pulmonary host defense are provided.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: August 30, 2022
    Assignee: REPONEX PHARMACEUTICALS A/S
    Inventor: Lars Heslet
  • Patent number: 11426429
    Abstract: Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: August 30, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Samuel Strober, Robert Lowsky
  • Patent number: 11396539
    Abstract: The present invention relates to new anti-angiopoietin 2 (ANGPT2) neutralizing antibodies for therapeutic and diagnostic methods and composition using them.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: July 26, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Ryan Michael Fryer, Chao Zheng, Michael Dziegelewski, Pankaj Gupta
  • Patent number: 11395826
    Abstract: An immunoregulatory agent containing a regulatory agent that regulates Dedicator of cytokinesis 2 (DOCK2)-mediated Rac activation as an active ingredient is provided.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: July 26, 2022
    Assignee: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
    Inventors: Yoshinori Fukui, Takehito Uruno, Yuki Sugiura
  • Patent number: 11376266
    Abstract: The present invention is directed to provide antitumor agent including water-soluble sulfasalazine as an active ingredient. Antitumor agents were obtained with, as the water-soluble sulfasalazine, a PEG-modified sulfasalazine represented by the following formula: wherein an average value of n is 4 or larger and 1136 or smaller.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: July 5, 2022
    Assignees: Keio University, Tokyo Institute of Technology
    Inventors: Hideyuki Saya, Osamu Nagano, Kenji Tsuchihashi, Kentaro Suina, Nobuhiro Nishiyama, Hiroyasu Takemoto, Takahiro Nomoto, Makoto Matsui, Keishiro Tomoda, Naoki Yamada, Tsukasa Nishimori
  • Patent number: 11377691
    Abstract: The present invention relates to methods that use novel biomarkers for diagnosing and/or treating Kawasaki diseases. The novel biomarkers of the invention show altered cytosine methylations state of certain CpG loci in subject with Kawasaki Disease relative to subject without Kawasaki diseases. Also provided are kits comprising at least one primer or reagent specific for the altered cytosine methylation state of certain CpG loci to detect Kawasaki Disease.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: July 5, 2022
    Assignee: Chang Gung Memorial Hospital, Kaohsiung
    Inventors: Ying-Hsien Huang, Ho-Chang Kuo
  • Patent number: 11365392
    Abstract: The present invention relates to a method for ex vivo generating and expanding MHCII restricted CD4+ Foxp3+ regulatory T cells, and therapeutic uses thereof. The inventors here demonstrated the optimal conditions for inducing Foxp3 expression in naive CD3+ CD4+ TCR??+ MHCII restricted T following polyclonal or following antigen-specific activation. They also developed an experimental procedure to generate autologous CD8+ T cell lines functionally committed to lyse tumor-antigen specific FOXP3 expressing TCR??+ MHCII restricted T cells, pathogenic CD4+ T cells that favour tumor cell immune evasion. In particular, the present invention relates to a method for generating ex vivo MHCII restricted CD4+ Foxp3+ regulatory T cells having the following phenotype: CD3+ CD4+ Foxp3+.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: June 21, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), MEDECINE ET INNOVATION, UNIVERSITÉ PARIS DIDEROT—PARIS 7, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Daniel Zagury, Helene Le Buanec, Sophie Duchez, Valerie Schiavon, Armand Bensussan
  • Patent number: 11313862
    Abstract: The method for aiding ALS detection provided by the present invention includes determining a profile of signal peptides contained in a bodily fluid from a test subject, and comparing the signal peptide profile thus determined for the test subject with a previously-determined profile of signal peptides in a bodily fluid from a healthy subject. The presence of a difference between the signal peptide profile of the test subject and the signal peptide profile of the healthy subject at a specific molecular weight is then associated with the test subject's suffering from or developing ALS.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: April 26, 2022
    Assignees: Toagosei Co., Ltd., National University Corporation Nagoya University
    Inventors: Nahoko Baileykobayashi, Makoto Sawada, Tetsuhiko Yoshida
  • Patent number: 11291725
    Abstract: The present invention relates to a novel protein formulation. In particular, the invention relates to a liquid pharmaceutical composition of tocilizumab, a method of manufacturing the composition, a kit including the composition, a package including the composition and to methods of treatment using the composition and/or package.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: April 5, 2022
    Assignee: FRESENIUS KABI DEUTSCHLAND GMBH
    Inventors: Jan Jezek, Luca Badiali, David Gerring
  • Patent number: 11278682
    Abstract: A device for delivering a predetermined amount of a substance within at least one body cavity of a subject, where the predetermined amount is at an effective amount for treatment of obesity or binge eating disorder. The device includes (a) A volume to contain the predetermined amount of the substance. (b) A delivery end placeable in proximity to the body cavity. The delivery end is in fluid communication with the volume and comprises at least one orifice. (c) A valve mechanically connected to the volume, with at least two configurations: (i) an active configuration configured to deliver the predetermined amount of the substance; and, (ii) an inactive configuration, in which the valve prevents delivery of the predetermined amount of the substance. (d) A fluid tight chamber configured to contain a predetermined volume of pressurized gas at a predetermined pressure.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: March 22, 2022
    Assignee: SIPNOSE LTD.
    Inventors: Daniel Shahaf, Iris Shichor
  • Patent number: 11278605
    Abstract: The present invention relates to a method for the preparation of an immunogenic lysate from mesothelioma tumor cells, to such a lysate and to dendritic cells loaded with the lysate, the present invention further relates a pharmaceutical composition comprising such lysate or dendritic cells, to the use of the lysate, and to said loaded dendritic cells or said pharmaceutical composition for use in the prevention or treatment of mesothelioma.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: March 22, 2022
    Assignee: AMPHERA B.V.
    Inventors: Josephus Petrus Johannes Jacobus Hegmans, Joan Geertrudis Jacobus Victor Aerts
  • Patent number: 11219655
    Abstract: The invention relates to medicines, and more particularly to an abortion medication and an administration thereof, where the abortion medication contains 40-60 mg/mL of a kidney bean lectin. The invention also provides another abortion medication, which contains 40-60 mg/mL of a kidney bean lectin, 40-50 mg/mL of an oligosaccharide and 6-9 mg/mL of NaCl. The two abortion medications provided herein are both capable of effectively terminating the pregnancy and are safe without toxic side effects. Moreover, these drugs can be reused several times. These abortion medications are administered intrauterinely, which enables the kidney bean lectin therein to show the best abortive effect, and the local administration of these drugs in the uterine cavity has relatively simple operation.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: January 11, 2022
    Assignee: YUNNAN KANG-ZHOU BIOTECH CO., LTD.
    Inventors: Kangmin Wang, Hong Zhao, Guizhen Lu, Chun Wu, Lifen Zhang, Chenghuan Yang, Jingjing Wang
  • Patent number: 11213512
    Abstract: Compositions comprising bis(tryptophan) derivatives are provided that act as antimicrobials. Also provided are methods for reversing antibiotic resistance in a bacterium, or recovering or enhancing antimicrobial activity of an antibiotic against a variety of microbes, by co-administration with a bis(tryptophan) derivative.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: January 4, 2022
    Assignee: The Curators of the University of Missouri
    Inventors: George W Gokel, Joseph W Meisel, Mohit B Patel
  • Patent number: 11213610
    Abstract: Compositions and blends of biopolymers and bio-acceptable polymers are described, along with the use of benign solvent systems to prepare biocompatible scaffolds and surgically implantable devices for use in supporting and facilitating the repair of soft tissue injuries.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: January 4, 2022
    Assignee: EMBODY INC.
    Inventors: Michael P. Francis, Yas Maghdouri-White, Hilary Wriggers, Nardos Sori, Stella Petrova, Seth Polk, Nicholas Thayer
  • Patent number: 11209440
    Abstract: This invention relates generally to compositions and methods for identifying the regulatory network that modulates, controls or otherwise influences T cell balance, for example, Th17 cell differentiation, maintenance and/or function, as well compositions and methods for exploiting the regulatory network that modulates, controls or otherwise influences T cell balance in a variety of therapeutic and/or diagnostic indications. This invention also relates generally to identifying and exploiting target genes and/or target gene products that modulate, control or otherwise influence T cell balance in a variety of therapeutic and/or diagnostic indications.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: December 28, 2021
    Inventors: Vijay Kuchroo, Aviv Regev, Jellert Gaublomme, Youjin Lee, Alexander K. Shalek, Chao Wang, Nir Yosef, Hongkun Park
  • Patent number: 11179412
    Abstract: A method of treating a patient having an elevated inflammatory response, such as an elevated Type I interferon response, is provided. The method can be used to treat sepsis. The method comprises administering to a patient having an elevated inflammatory response, an inhibitor of anaplastic lymphoma kinase (ALK inhibitors) or expression of ALK, in an amount effective to treat the elevated inflammatory response.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: November 23, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Daolin Tang, Timothy Billiar, Ling Zeng
  • Patent number: 11167005
    Abstract: Compositions and methods for the treatment of Sjogren's syndrome (SS) and SS-related symptoms in human subjects are described. The compositions comprise synthetic peptides based on the sequence of CDR1 of an anti-DNA monoclonal antibody.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: November 9, 2021
    Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventor: Edna Mozes
  • Patent number: 11161881
    Abstract: Described is a composition comprising a peptide which consists of 7-17 adjacent amino acids and comprises the hexamer TX1EX2X3E, where X1, X2, and X3 can be any natural or non-natural amino acid, and the peptide is cyclized and does not exhibit TNF receptor binding activity, and an inhibitor of viral neuraminidase.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: November 2, 2021
    Assignee: Apeptico Forschung UND Entwicklung GMBH
    Inventors: Bernhard Fischer, Rudolf Lucas, Hendrik Fischer
  • Patent number: 11149087
    Abstract: Methods and compositions for generating immune responses using adenovirus vectors that allow multiple vaccinations or in combination with other therapy and vaccinations in individuals with preexisting immunity to adenovirus are provided.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: October 19, 2021
    Assignee: Etubics Corporation
    Inventors: Frank R. Jones, Elizabeth Gabitzsch, Yvette Latchman, Adrian Rice
  • Patent number: 11129976
    Abstract: The object of the present invention is to provide a test method using a novel administration method of an extract from inflamed tissues inoculated with vaccinia virus or a preparation containing the extract. It has been demonstrated that by sustainedly administering an extract from inflamed tissues inoculated with vaccinia virus or a preparation containing the extract by using a continuous administration device according to the present invention, a comparable effect is exerted at a very low dose compared with conventional administration methods such as oral administration. Therefore, the present invention can provide a test method using animals requiring less burden on a researcher, a treatment of patient at a low dose, and the like.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: September 28, 2021
    Assignees: OSAKA UNIVERSITY, NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki Tanaka, Tsuyoshi Murase, Hideki Yoshikawa, Mitsuru Naiki, Tomonori Matsumoto
  • Patent number: 11130816
    Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: September 28, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
  • Patent number: 11117942
    Abstract: Compositions and methods are provided for treating companion animals are provided. An adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding erythropoietin (EPO). In desired embodiments, the subject is a cat or dog.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: September 14, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Christian Hinderer, James M. Wilson, Matthew Wilson
  • Patent number: 11117969
    Abstract: This application relates generally to the production of polypeptides having specific antigen-binding properties of Fv domains, for example, insertable variable fragments of antibodies, and modified ?1-?2 domains of NKG2D ligands. This application further relates to modified ?1-?2 domains of NKG2D ligands attached to polypeptides, in some embodiments antibodies or fragments of antibodies. This application further relates to antigen-binding peptides derived from light and heavy chain antibody variable domains, which contain two linker regions and a split variable domain.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: September 14, 2021
    Assignee: XYPHOS BIOSCIENCES INC.
    Inventors: Kyle Landgraf, Daniel P. Steiger, Steven R. Williams, David W. Martin, Jr., Dana Gebhart, Tarah Baron
  • Patent number: 11103524
    Abstract: The present invention concerns a solid, palatable composition and its preparation process which, relative to the total weight of the composition, comprises: 5 to 30%, preferably 8 to 20% by weight of at least one fat chosen from among a liquid oil, a fat, wax or mixture thereof, the liquid oil not to represent more than 8% by weight of the composition; 0.001 to 85% by weight of at least one active substance; and 20 to 95%, preferably 40 to 70% by weight of at least one palatable material, for use thereof as medicinal product, nutraceutical or food supplement, for oral administration to mammals, except man, in particular for domestic animals such as dogs, cats or horses. The said solid composition is obtained by mixing the components, vaporising the fats, calibrating the dry, fluid granular material and compressing the granular material in a stock cube press.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: August 31, 2021
    Assignee: Friulchem Spa
    Inventors: Guy Derrieu, Giancarlo Mazzola
  • Patent number: 11098106
    Abstract: The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: August 24, 2021
    Assignee: Axon Neuroscience SE
    Inventors: Michal Novák, Eva Kontseková, Branislav Kovácech, Norbert Zilka
  • Patent number: 11083788
    Abstract: The present invention provides methods and compositions for the stimulation of immune responses and for treating or preventing allergic disease and responses and inflammatory disease and responses. In particular, the present invention provides nanoemulsion compositions and methods of using the same for the induction of immune responses that prevent or treat allergic disease by reducing allergic response. Compositions and methods of the invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: August 10, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: James R. Baker, Jr., Anna U. Bielinska, Douglas Smith, Paul E. Makidon, Jessica J. O'Konek
  • Patent number: 11085088
    Abstract: The present disclosure provides for and relates to cancer treatment based on the identification of novel biomarkers for diagnosis and prognosis of prostate cancer or the biochemical reoccurrence of prostate cancer. The biomarkers of the invention show altered methylation levels of certain CpG loci relative to normal prostate tissue, as set forth.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: August 10, 2021
    Assignees: HudsonAlpha Institute for Biotechnology, BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Richard M Myers, James D Brooks, Marie K Kirby
  • Patent number: 11046759
    Abstract: The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: June 29, 2021
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Stephen James Moore, Margaret Thy Luu Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett, James William West
  • Patent number: 11047858
    Abstract: A method for detecting and typing rare tumor cells having high metabolic activity in a body fluid sample, comprising the following steps: incubating nucleated cells in a body fluid sample with a first metabolic marker and a second metabolic marker capable of producing fluorescence signals; detecting, by means of high-throughput imaging, uptake of all the fluorescence signals of the metabolic markers by cells, so as to determine the energy metabolism mode and intensity of the cells; and identifying and typing, according to the fluorescence signals of the metabolic marker combination, tumor cells having high metabolic activity in the body fluid sample. Further provided is a kit used for the detecting and typing method, comprising a microwell array chip, a first metabolic marker and a second metabolic marker capable of producing fluorescence signals, and fluorescence-labeled antibodies specific to leukocyte common antigen.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: June 29, 2021
    Assignee: Suzhou Junhui Biotechnology Co., Ltd.
    Inventors: Qihui Shi, Yuliang Deng, Yin Tang, Zhuo Wang
  • Patent number: 11045500
    Abstract: A three-dimensional fibrin engineered tissue construct is provided selected from: (i) a fibrin gel matrix comprising a combination of tissue-specific cells and at least one type of vascular cells; and (ii) a hybrid scaffold of fibrin gel and a polymeric synthetic scaffold comprising at least one type of vascular cells or a combination of tissue-specific cells and at least one type of vascular cells.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: June 29, 2021
    Assignee: TECHNION RESEARCH DEVELOPMENT FOUNDATION LTD.
    Inventors: Shulamit Levenberg, Ayelet Lesman
  • Patent number: 11040110
    Abstract: Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: June 22, 2021
    Assignee: HANMI SCIENCE CO., LTD.
    Inventors: Dae Hae Song, Jae Hee Shin, Mi Ji Lee, Sung Hee Hong, Se Chang Kwon, Gwan Sun Lee
  • Patent number: 10982190
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: April 20, 2021
    Assignee: SDF BioPharma Inc.
    Inventors: Gerald F. Swiss, David Kiewlich
  • Patent number: 10967008
    Abstract: The present invention relates to methods for the preparation of compositions comprising adipose tissue-derived secretions, for example those derived from bovine adipose tissue, and the use of such compositions in the preparation of a pharmaceutical composition for topical use. The invention also relates to the use of adipose tissue-derived secretions and pharmaceutical compositions thereof for the topical treatment of a non-inflammatory condition, for example the treatment of a skin condition, and for the stimulation of hair growth in a subject by topical application. The invention also relates to the use of adipose tissue-derived secretions and pharmaceutical compositions thereof for the topical treatment of acne.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: April 6, 2021
    Assignee: Cell Ideas Pty Ltd
    Inventors: Graham Vesey, Rebecca Anne Webster
  • Patent number: 10960064
    Abstract: NK cells and NK cell lines are modified to increase cytotoxicity, wherein the cells and compositions thereof have a use in the treatment of cancer. Production of modified NK cells and NK cell lines is via genetic modification to remove checkpoint inhibitory receptor expression and/or add mutant (variant) TRAIL ligand expression.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: March 30, 2021
    Assignee: ONK THERAPEUTICS LIMITED
    Inventor: Michael O'Dwyer
  • Patent number: 10906957
    Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGF? trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: February 2, 2021
    Assignee: EpicentRx, Inc.
    Inventors: Christopher Larson, Tony R. Reid, Bryan T. Oronsky
  • Patent number: 10883116
    Abstract: The invention relates to transduction compounds, buffers and methods for introducing molecules into cells. The invention also relates to methods of treatment, pharmaceutical compositions and other uses of the transduction compounds and buffers. The invention also relates to modified cells obtainable by the transduction compounds, buffers and methods of the invention.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: January 5, 2021
    Assignee: Koninklijke Nederlandse Akademie van Wetenschappen
    Inventors: Niels Geijsen, Diego Sebastián D'Astolfo
  • Patent number: 10882911
    Abstract: Disclosed is a CD154 binding polypeptide that specifically recognizes CD154. The polypeptide according to the present disclosure effectively inhibits the CD154-CD40 interaction without activating platelets, and thus can be effectively used in the prevention or treatment of various T cell-mediated or antibody-mediated diseases or symptoms, which requires inhibition of the interaction.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: January 5, 2021
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: SeongHoe Park, Kyeong Cheon Jung
  • Patent number: 10869887
    Abstract: Engineered orthogonal cytokine receptor/ligand pairs, and methods of use thereof, are provided.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: December 22, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kenan Christopher Garcia, Jonathan Sockolosky, Lora Picton
  • Patent number: 10842743
    Abstract: Hyaluronic acid-based hydrogels, solutions for preparing such, and methods pertaining thereunto are disclosed with properties that include self-resorption, extended release of biologically active agents, and/or decreased degradation, denaturation, and/or functional inactivation of biologically active agents.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: November 24, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Michael D. Roth, Airi Harui
  • Patent number: 10835596
    Abstract: Compositions of a recombinant adenovirus based vector vaccine containing one or more flavivirus antigen genes are disclosed herein. Methods for constructing and producing such vaccines and methods of using these vaccines to generate immune responses against flaviviruses are also described. Compositions described herein allow for vaccinations in subjects with preexisting immunity to adenovirus.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: November 17, 2020
    Assignee: Etubics Corporation
    Inventors: Frank R. Jones, Joseph Balint, Adrian Rice, Yvette Latchman, Elizabeth Gabitzsch
  • Patent number: 10801065
    Abstract: Provided herein are methods of determining a subject's level of exposure to radiation and methods of determining a subject's risk of subsequent development of radiation disease or risk of poor prognosis from radiation exposure that include determining a level of one or more miRNAs selected from the group consisting of mouse and human homologues of mouse miR-130a-3p, miR-150-5p, miR-17-3p, miR-187-3p, miR-194-5p, miR-27a-3p, miR-30a-3p, miR-30c-5p, miR-142-5p, miR-342-3p, miR-34b-3p, miR-126-3p, miR-320-3p, miR-136-5p, miR-33-5p, miR-142a-3p, miR-706, miR-375-3p, miR-29a-5p, miR-193a-3p, miR-99b-5p, miR-151-3p, miR-let-7d-3p, miR-486-5p, miR-423-5p, miR-30b-5p, miR-191-5p, miR-497a-5p, miR-32-5p, miR-214-5p, miR-326-3p, miR-1195, miR-122-5p, miR-1839-3p, miR-500-3p, miR-30e-3p, miR-322-3p, miR-709, miR-486-3p, miR-133a-3p, miR-676-3p, miR-744-5p, miR-29a-3p, miR-1839-5p, miR-30a-5p, miR-199b-5p, miR-125a-5p, miR-133b-3p, miR-24-3p, miR-21a-5p, miR-503-5p, miR-328-3p, miR-let-7g-5p, miR-362-3p, miR-199a-5p, miR
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: October 13, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., Albert Einstein College of Medicine, Inc.
    Inventors: Dipanjan Chowdhury, Chandan Guha
  • Patent number: 10792338
    Abstract: A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of Erythropoietin and about 100-300 mg per cm2 wound tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject. Unit dosage forms, pharmaceutical compositions, cosmetic compositions and formulations comprising Erythropoietin and/or Fibronectin are also disclosed.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: October 6, 2020
    Assignee: Remedor Biomed Ltd.
    Inventor: Saher Hamed
  • Patent number: 10787643
    Abstract: The present invention relates to methods and kits for expanding a stem cell population. More particularly, the invention relates, inter alia, to methods, kits, and compositions for expanding a stem cell population, particularly a hematopoietic stem cell population.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: September 29, 2020
    Assignee: STOWERS INSTITUTE FOR MEDICAL RESEARCH
    Inventors: John M. Perry, Linheng Li, Justin C. Grindley
  • Patent number: 10722537
    Abstract: Provided herein are methods of treating cancer by activating resident memory T cells using one or more antigenic peptides.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: July 28, 2020
    Assignee: Regents of the University of Minnesota
    Inventors: David B. Masopust, Jr., Vaiva D. Vezys
  • Patent number: 10696725
    Abstract: The present invention relates to a glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: June 30, 2020
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Jung Kuk Kim, Young Jin Park, In Young Choi, Sung Youb Jung
  • Patent number: 10690677
    Abstract: Methods for identifying compounds that modulate cellular responses stimulated by IgE, which include providing an impedance-based system that monitors cell-substrate impedance of cells on a substrate; introducing cells to the substrate of the system; adding at least one test compound and IgE to the cells, wherein the at least one test compound is suspected of modulating cell responses stimulated by the IgE; adding an antigen to the cells; monitoring the cell-substrate impedance of cells on the substrate; and analyzing the cell-substrate impedance to evaluate whether the at least one test compound alters a cellular response to stimulation with the IgE.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: June 23, 2020
    Assignee: ACEA Biosciences, Inc.
    Inventors: Xiao Xu, Yama A. Abassi, Xiaobo Wang, Jiangbo Gan
  • Patent number: 10622675
    Abstract: A solvent useful for lithium batteries comprises a compound of Formula (I): (R1)(R2)(R3)Si—R4—O—C(O)—[(O—R5)n—(O—C(O)]m—O—R6—X1. Each of R1 and R2 independently is alkyl; R3 is alkyl, —X2—Si(R7)(R8)(R9), or —CH2—O—C(O)—O—R10; X1 is H or —Si(R11)(R12)(R13); each of R4 and R6 independently is alkylene; each R5 independently is C2 to C6 alkylene; each of R7, R8, R9, and R10 independently is alkyl; X2 is O or alkylene; each of R11 and R12 independently is alkyl; R13 is alkyl or —X3—Si(R14)(R15)(R16); each of R14, R15, and R16 independently is alkyl; X3 is O or alkylene; m is 0 or 1, and n is 1-3; and when m is 0 and R3 is alkyl, X1 is —Si(R11)(R12)(R13). Also described is a method for manufacturing a compound of Formula (II): (R17)(R18)(R19)Si—CH2—O—C(O)—O—R20 where each R17, R18, R19, and R20 is alkyl.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: April 14, 2020
    Assignee: UCHICAGO ARGONNE, LLC
    Inventors: Trevor L. Dzwiniel, Krzysztof Pupek, Gregory K. Krumdick
  • Patent number: 10617689
    Abstract: The present invention relates to compositions and methods for controlling glycaemia in a mammalian in need thereof. The present invention relates to compositions and methods for the treatment of diabetes disease and related disorders. More specifically, the present invention relates to novel therapies or combinatorial therapies of diabetes and related disorders, based on compositions controlling the blood glucose level.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: April 14, 2020
    Assignee: PHARNEXT
    Inventors: Daniel Cohen, Ilya Chumakov, Serguei Nabirochkin, Rodolphe Hajj
  • Patent number: 10610570
    Abstract: This document provides methods and materials related to treating rotator cuff conditions (e.g., rotator cuff tendonitis or rotator cuff injuries such as partial rotator cuff tears). For example, methods and materials for using BMP-5 polypeptides to treat rotator cuff conditions as well as methods and materials for using inhibitors of SIRT6, SIRT7, and/or HDAC10 polypeptide expression or activity to treat rotator cuff conditions are provided.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: April 7, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Scott M. Riester, John W. Sperling, Andre J. van Wijnen